nach oben

Journal of Assisted Reproduction and Genetics

Erschienen in:

01.03.2012 | Fertility Preservation

Oocyte cryopreservation in a patient with sickle cell disease prior to hematopoietic stem cell transplantation: first report

verfasst von: Serena Dovey, Lakshmanan Krishnamurti, Joseph Sanfilippo, Sriya Gunawardena, Patricia Mclendon, Mary Campbell, Sandra Alway, Brenda Efymow, Clarisa Gracia

Erschienen in: Journal of Assisted Reproduction and Genetics | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To report the first occurrence of successful ovarian stimulation, oocyte retrieval and oocyte cryopreservation for fertility preservation in an adolescent with severe sickle cell disease scheduled to undergo a hematopoietic stem cell transplant

Methods

Case report

Results

A 19 year old female with severe sickle cell disease presented for fertility preservation counseling prior to hematopoietic stem cell transplantation. She ultimately underwent ovarian stimulation using a minimal stimulation GnRH antagonist protocol resulting in the successful banking of oocytes prior to transplant. The unique hazards associated with ovarian stimulation in patients with sickle cell disease, such as thrombosis and vaso-occlusive events, are discussed and the methods undertaken to minimize these risks are described.

Conclusions

Controlled ovarian hyperstimulation and oocyte banking for fertility preservation is feasible in young women with sickle cell disease requiring hematopoietic stem cell transplant and deserves further investigation. Given the elevated risk of thrombosis and predisposition to painful vaso-occlusive events, controlled ovarian hyperstimulation in patients with sickle cell disease is not straightforward and requires a multi-disciplinary team approach to adequately address and minimize the risks in this unique patient population.

Abboud RM. Hematopoietic stem-cell transplantation for adults with sickle cell disease. N Engl J Med. 2009;361(24):2380–81.PubMedCrossRef

Ohene-Frempong K, Weiner SJ, Sleeper LA, Miller ST, Embury S, Moohr JW, Wethers DL, Pegelow CH, Gill FM. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91(1):288–94.PubMed

Minter KR, Gladwin MT. Pulmonary complications of sickle cell anemia. A need for increased recognition, treatment, and research. Am J Respir Crit Care Med. 2001;164(11):2016–19.PubMed

Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP. Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med. 1994;330(23):1639–44.PubMedCrossRef

Walters MC, Hardy K, Edwards S, Adamkiewicz T, Barkovich J, Bernaudin F, Buchanan GR, Bunin N, Dickerhoff R, Giller R, et al. Pulmonary, gonadal and central nervous system status after bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2010;16:263–72.PubMedCrossRef

Sklar C. Maintenance of ovarian function and risk of premature menopause related to cancer treatment. J Natl Cancer Inst Monogr. 2005:25–7.

Schimmer AD, Quatermain M, Imrie K, Ali V, McCRae J, Stewart AK, Crump M, Derzko C, Keating A. Ovarian function after autologous bone marrow transplantation. J Clin Oncol. 1998;16:2359–63.PubMed

Thibaud E, Rodriguez-Macias K, Trivin C, Esperou H, Michon J, Brauner R. Ovarian function after bone marrow transplantation during childhood. Bone Marrow Transplant. 1998;21:287–90.PubMedCrossRef

Sarafoglou K, Boulad F, Gillio A, Sklar C. Gonadal function after bone marrow transplantation for acute leukemia during childhood. J Pediatr. 1997;130:210–6.PubMedCrossRef

10.

Matsumoto M, Shinohara O, Ishiguro H, et al. Ovarian function after bone marrow transplantation performed before menarche. Arch Dis Child. 1999;80:452–4.PubMedCrossRef

11.

Sanders JE, Hawley J, Levy W, et al. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood. 1996;87:3045–52.PubMed

12.

Mayer EI, Dopfer RE, Klingebiel T, Scheel-Walter H, Ranke MB, Neithammer D. Longitudinal gonadal function after bone marrow transplantation for acute lymphoblastic leukemia during childhood. Pediatr Translant. 1999;3(1):38–44.CrossRef

13.

Vlachapapodopoulou E, Kitra V, Peristeri J, Goussetis E, Karachaliou F, Petropoulos D, Fotinou A, Michalacos S, Graphakos S. Gonadal function of young patients with beta-thalassemia following bone marrow transplantation. J Pediatr Endocrinol Metab. 2005;18(5):477–83.CrossRef

14.

Noyes N, Porcu E, Borini A. Over 900 oocyte cryopreservation babies born with no apparent increase in congenital anomalies. Reprod Biomed Online. 2009;18:769–76.PubMedCrossRef

15.

Ataga KI, Orringer EP. Hypercoagulability in sickle cell disease: a curious paradox. Am J Med. 2003;115:721–28.PubMedCrossRef

16.

Charneski L, Congdon HB. Effects of antiplatelet and anticoagulant medications on the vasoocclusive and thrombotic complications of sickle cell disease: a review of the literature. Am J Health Syst Pharm. 2010;67:895–900.PubMedCrossRef

17.

Smith GD, Serafina PC, Fioravanti J, Yadid I, Coslovsky M, Hassun P, Alegretti JR, Motta EL. Prospective randomized comparison of human oocytes cryopreservation with slow-rate freezing or vitrification. Fertil Steril. 2010;94(6):2088–95.PubMedCrossRef

18.

Shalet SM, Didi M, Ogilvy-Stuart AL, Schulga J, Donaldson MD. Growth and endocrine function after bone marrow transplantation. Clin Endocrinol (Oxf). 1995;42:333–9.CrossRef

19.

Schubert MA, Sullivan KM, Schubert MM, et al. Gynecological abnormalities following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1990;5:425–30.PubMed

20.

Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24:2917–31.PubMedCrossRef

21.

Cobo A, Domingo J, Perez S, Crespo J, Remohi J, Pellicer A. Vitrification: an effective new approach to oocyte banking and preserving fertility in cancer patients. Clin Transl Oncol. 2008;10:268–73.PubMedCrossRef

22.

Oktay K, Cil AP, Bang H. Efficiency of oocyte cryopreservation: a meta-analysis. Fertil Steril. 2006;86:70–80.PubMedCrossRef

23.

Practice Committee of the American Society of Reproductive Medicine. Ovarian tissue and oocyte cryopreservation. Fertil Steril. 2008;90:S241–246.

24.

Donnez J, Silbers S, Andersen CY, Demeestere I, Piver P, Meirow D, Pellicer A, Dolmans MM. Children born after autotransplantation of cryopreserved ovarian tissue: a review of 13 live births. Ann Intern Med. 2011;43:437–50.

25.

Roux C, Amiot C, Agnani G, Aubard Y, Rohrlich PS, Piver P. Live birth after ovarian tissue autograft in a patient with sickle cell disease treated by allogeneic bone marrow transplantation. Fertil Steril. 2010;93(7):2413.e15–9.CrossRef

26.

Kirkpatrick MB, Haynes J. Sickle cell disease and the pulmonary circulation. Semin Respir Crit Care Med. 1994;15:473–81.CrossRef

27.

Ataga KI. Hypercoagulability and thrombotic complications in hemolytic anemia. Hematologica. 2009;94(11):1481–84.CrossRef

28.

Villers MS, Jamison MG, DeCastro LM, James AH. Morbidity associated with sickle cell disease in pregnancy. Am J Obste Gynecol. 2008;199:125.e1–5.CrossRef

29.

American College of Obstetricians and Gynecologists Practice Bulletin. Use of hormonal contraception in women with coexisting medical conditions. ACOG Practice Bulletin No 73; 2006:1–20.

30.

Chan WS, Dixon ME. The “ART” of thromboembolism: a review of assisted reproductive technology and thromboembolic complications. Thromb Res. 2008;121:713–26.PubMedCrossRef

31.

Stewart JA, Hamilton PJ, Murdoch AP. Thromboembolic disease associated with ovarian stimulation and assisted conception techniques. Hum Reprod. 1997;12(10):2167–73.PubMedCrossRef

32.

Vloeberghs V, Peeraer K, Pexsters A, D’Hooghe T. Ovarian hyperstimulation syndrome and complications of ART. Best Pract Res Clin Obstet Gynaecol. 2009;23:691–709.PubMedCrossRef

33.

Kol S, Itskovitz-Eldor J. Gonadotropin-releasing hormone agonist trigger: the way to eliminate ovarian hyperstimulation syndrome—a 20 year experience. Semin Reprod Med. 2010;28(6):500–5.PubMedCrossRef

34.

Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective, randomized controlled study. Fertil Steril. 2008;89(1):84–91.PubMedCrossRef

35.

Stuart MJ, Nagel R. Sickle-cell disease. Lancet. 2004;364:1343–60.PubMedCrossRef

36.

National Institute of Health, National Heart, Lung and Blood Institute, Division of Blood Diseases and Resources. The management of sickle cell disease. NIH Publication No 02-2117, 4th edition, 2002: 1–188

37.

Ballas SK. Sickle cell anaemia: progress in pathogenesis and treatment. Drugs. 2002;62(8):1143–72.PubMedCrossRef

38.

Benjamin LJ, Dampier CD, Jacox AK et al. Guidelines for the management of acute and chronic pain in sickle cell disease. APS clinical practice guideline series no 1. Glenview, IL, 1999.

39.

Morrissey LK, O’Brian Shea J, Kalish LA, Weiner DL, Branowicki P, Heeney MW. Clinical practice guideline improves the treatment of sickle cell disease vasoocclusive pain. Pediatr Blood Cancer. 2009;52:369–72.PubMedCrossRef

Titel: Oocyte cryopreservation in a patient with sickle cell disease prior to hematopoietic stem cell transplantation: first report
verfasst von: Serena Dovey
Lakshmanan Krishnamurti
Joseph Sanfilippo
Sriya Gunawardena
Patricia Mclendon
Mary Campbell
Sandra Alway
Brenda Efymow
Clarisa Gracia
Publikationsdatum: 01.03.2012
Verlag: Springer US
Erschienen in: Journal of Assisted Reproduction and Genetics / Ausgabe 3/2012
Print ISSN: 1058-0468
Elektronische ISSN: 1573-7330
DOI: https://doi.org/10.1007/s10815-011-9698-2

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Oocyte cryopreservation in a patient with sickle cell disease prior to hematopoietic stem cell transplantation: first report